As IRS-1 and IRS-2 are thought to mediate most of the effects of IR and IGF-1R in breast cancer cells, it may be possible to disrupt this molecule without affecting normal glucose homeostasis mediated by other adapter proteins in insulin target organs. Here, INSR is linked to breast carcinoma.